ZITHROMAX | Acute Bacterial Sinusitis | PfizerPro XX (country)

Administration

Pathogens

Epidemiology

Efficacy

Tab Number 5

Administration

Adults¹

500 mg once daily for 3 days, or an alternative of 500 mg on Day 1, then 250 mg daily on Days 2-5

Pediatrics¹

10 mg/kg once daily for 3 days, or an alternative of 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5

ZITHROMAX should be given as a single daily dose¹
ZITHROMAX tablets and suspension can be taken with or without food¹
ZITHROMAX tablets should only be administered to children weighing more than 45 kg¹
Administration of ZITHROMAX suspension should follow adults dosage for children weighing more than 45 kg¹

Resources

Pediatrics: How to Properly Administer ZITHROMAX®

Watch now

Renal Impairment¹

No dose adjustment is necessary in patients with mild to moderate renal impairment (glomerular filtration rate [GFR] of 10–80 mL/min). Caution should be exercised when ZITHROMAX is administered to patients with severe renal impairment (GFR <10 mL/min)

Hepatic Impairment¹

The same dosage as in patients with normal hepatic function may be used in patients with mild to moderate hepatic impairment

Pathogens

Main Bacterial Pathogens²

Streptococcus pneumoniae and Haemophilus influenzae are the two main bacterial pathogens, accounting for more than 50% of bacterial infections
Moraxella catarrhalis is a less common pathogen in adults, but accounts for 25% of cases in children
Streptococcus pyogenes, Staphylococcus aureus, gram-negative bacilli, and oral anaerobes are also less common pathogens

Epidemiology

Approximately 6% to 7% of children with respiratory symptoms have acute rhinosinusitis (ARS). An estimated 16% of adults are diagnosed with acute bacterial rhinosinusitis annually³

ARS accounts for 1 in 5 antibiotic prescriptions for adults, making it the fifth most common reason for an antibiotic prescription³

Efficacy

ZITHROMAX – A single daily dose delivers high success rates in upper respiratory tract infections⁴

Clinical Success Rate Following Treatment With Azithromycin in Adults >18 Years

Adapted from Donde et al. 2014⁴

Clinical Success Rate Among Children and Adolescents Age ≤18 years

Adapted from Donde et al. 2014⁴

Donde et al. 2014⁴

An open-label, prospective, multicenter, non-interventional study to assess the safety and tolerability of azithromycin in acute bacterial upper respiratory tract infections (URTIs)
Primary objective: assess the effectiveness of azithromycin in acute bacterial URTIs
In general, in children a total single dose of 30 mg/kg was given over a period of 3–5 days; the maximum recommended total dose of azithromycin was 1,500 mg
Overall success rate for clinical outcome in the evaluable (278 of 410) population was 98.92%

ZITHROMAX – Clinical Cure Rates as Effective as Erythromycin When Treating Sinusitis⁵

Adapted from Felstead et al. 1991⁵

Felstead et al. 1991⁵

Two randomized, multicenter studies comparing azithromycin and erythromycin in the treatment of URTIs
Clinical cure was recorded in 84/101 (83%) treated with azithromycin, and in 85/108 (79%) erythromycin-treated URTI patients
Cure rates in sinusitis were 85% in the 68 patients treated with azithromycin, and 75% in the 74 patients treated with erythromycin